Advertisement

Topics

Xbrane, Stada to co-develop Xlucane; Stada gets commercialization rights

15:41 EDT 13 Jul 2018 | Elsevier Business Intelligence

Xbrane Biopharma AB and Stada Arzneimittel AG are teaming up to co-develop the former’s ophthalmic therapy Xlucane in the U...

Original Article: Xbrane, Stada to co-develop Xlucane; Stada gets commercialization rights

NEXT ARTICLE

More From BioPortfolio on "Xbrane, Stada to co-develop Xlucane; Stada gets commercialization rights"

Advertisement
Quick Search
Advertisement
Advertisement